Defensible Algorithms: How Evidence-Based AI is Reshaping Prior Authorization

SEATTLE – November 05, 2026

For decades, the structural friction of the American healthcare system has been most acutely felt in the bureaucratic choke point of utilization management. Health plans, tasked with controlling costs, have historically relied on manual prior authorization processes that frustrate providers, delay patient care, and contribute to widespread clinician burnout. In recent years, artificial intelligence has been heralded as the ultimate solvent for this administrative gridlock. Yet, as the technology has been deployed, a new crisis of trust has emerged, characterized by physician pushback against opaque algorithms and regulatory scrutiny over automated "robo-denials."

The central challenge for the healthcare marketplace is no longer simply automating the review process; it is proving that the automation is clinically sound, ethically defensible, and fully transparent. This structural shift from mere speed to "defensible efficiency" is the strategic rationale behind a pivotal presentation scheduled for the upcoming HLTH 2026 conference in Las Vegas, where MCG Health and Telligen will unveil the results of a real-world case study on AI-enabled medical necessity reviews.

Bridging the Trust Gap in Utilization Management

The healthcare industry is currently navigating a precarious transition. On one side, organizations face mounting pressure to comply with stringent new regulations, such as the Centers for Medicare & Medicaid Services (CMS) Interoperability and Prior Authorization final rule (CMS-0057-F), which mandates significantly shorter response times for prior authorization requests. On the other side, influential bodies like the American Medical Association (AMA) and the American Hospital Association (AHA) have raised intense alarms regarding the "black box" nature of certain AI tools, warning that algorithmic bias could lead to arbitrary care denials.

To bridge this trust gap, AI must be tethered to something the medical community already respects: peer-reviewed, evidence-based clinical guidelines. MCG Health, a division of the Hearst Health network, has built its market position on providing these exact guidelines. By integrating artificial intelligence with its established clinical criteria, the company is attempting to shift the paradigm from generative guesswork to deterministic, rule-bound decision support.

Daniel Cawood, Senior Manager of Product Management at MCG Health, highlighted this strategic alignment ahead of the conference. "At our session, HLTH attendees will hear the successful results of a real-world case study where AI supported improved efficiency of medical necessity reviews and reduced review time while keeping decisions grounded in nationally recognized, evidence-based guidelines," Cawood stated. "We'll also discuss how making those guidelines the transparent foundation for an AI-supported review can help support more clinically rigorous decisions."

This approach addresses the core anxiety of healthcare providers. When an algorithm's logic can be explicitly traced back to a recognized clinical standard, it ceases to be a black box. Instead, it becomes a "glass box," offering an auditable trail that is crucial for regulatory compliance and patient appeals.

The Operational Shift: Humans in the Loop

The theoretical promise of transparent AI is only as valuable as its practical application on the clinical floor. This is where Telligen, an employee-owned population health management company and a CMS-designated Quality Innovation Network-Quality Improvement Organization (QIN-QIO), provides a critical operational lens. With over 50 years of experience partnering with federal and state agencies, Telligen represents the operational boots on the ground in the utilization management ecosystem.

The integration of AI into Telligen's workflows illustrates a broader industry trend toward the "human-in-the-loop" model. In this framework, artificial intelligence does not replace the human clinician; rather, it handles the high-volume, routine data extraction and initial triage, augmenting the human reviewer's capacity. By automating the administrative heavy lifting, the technology allows highly trained nurses and medical directors to redirect their cognitive resources toward complex, high-acuity cases that require nuanced clinical judgment.

Nancy Johnson, BSN, RN, Senior Manager of Quality Improvement at Telligen, detailed the operational impact of this integration. "At Telligen, we've seen firsthand how AI-enabled medical necessity review tools can transform the utilization management process," Johnson noted. "By combining the power of artificial intelligence with MCG's evidence-based clinical guidelines, we've been able to accelerate our review timelines without compromising quality or clinical integrity. This approach has enabled our team to focus more on complex cases while ensuring every decision remains defensible and aligned with best practices. We're excited to share our results and insights with the HLTH community."

For healthcare operations leaders, this operational shift is profound. It demonstrates that the return on investment for clinical AI is not solely measured in headcount reduction, but in the optimization of clinical expertise. By mitigating nurse reviewer burnout and ensuring that complex cases receive the dedicated human attention they deserve, organizations can achieve a delicate balance between operational efficiency and patient safety.

The Interoperability Imperative

While the MCG and Telligen case study offers a blueprint for defensible utilization management, scaling such solutions across the broader healthcare landscape reveals a significant structural hurdle: data fragmentation. Artificial intelligence algorithms, no matter how sophisticated or well-grounded in clinical guidelines, are fundamentally constrained by the quality and completeness of the data they ingest. In an industry notorious for siloed electronic health records (EHRs) and incompatible IT systems, incomplete patient histories present a formidable barrier to accurate AI-driven decision support.

Recognizing this bottleneck, the HLTH 2026 agenda features a parallel discussion that strikes at the heart of the issue. MCG Vice President of Health AI Products, Naqi Khan, MD, MS, FAMIA, will participate in a panel appropriately titled "Data You Can Trust: AI, Interoperability, and the Race for a Unified Patient Record." Joining executives from IBM and b.well Connected Health, Dr. Khan's panel underscores the strategic reality that interoperability and clinical AI are inextricably linked.

One healthcare technology analyst recently observed that the race for a unified patient record is the foundational infrastructure project of the 21st-century health system. Without seamless data exchange standards—such as Fast Healthcare Interoperability Resources (FHIR)—AI models are effectively operating blindfolded. The collaboration between clinical content providers, technology giants, and interoperability platforms highlights the cross-sector partnerships required to untangle the data web.

The Future of Defensible Care

The competitive landscape for clinical decision support is intensifying rapidly. Dominant EHR vendors like Epic are aggressively embedding AI capabilities directly into their core platforms, leveraging their massive footprint within health systems. Payer-aligned juggernauts like Optum possess unparalleled data scale, while nimble disruptors like Cohere Health are attempting to fundamentally redesign the prior authorization workflow from the ground up.

In this crowded marketplace, the differentiator will not be who has the fastest algorithm, but who has the most trustworthy one. As regulatory frameworks tighten and both providers and patients demand greater accountability, the burden of proof is shifting. Health plans and population health organizations can no longer afford to deploy solutions that prioritize administrative speed at the expense of clinical transparency.

The upcoming presentation by MCG Health and Telligen at HLTH 2026 serves as a bellwether for the industry. It signals a maturation of the market, moving past the initial hype cycle of artificial intelligence and into the rigorous, unglamorous work of operational integration. By anchoring advanced algorithms to established clinical truths, these organizations are mapping a sustainable path forward—one where technology accelerates the delivery of care without ever losing sight of the medical evidence that justifies it. The enterprises that master this synthesis of speed and defensibility will be the ones that define the future of healthcare competition.